Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05847361
Other study ID # Tunis Elmanar university
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 15, 2023
Est. completion date December 6, 2023

Study information

Verified date December 2023
Source University Tunis El Manar
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

tetrahydrobiopterin (BH4) is degraded by several enzymes, including BH4 oxidase and peroxidases. Several factors can affect its synthesis and degradation. BH4 deficiency or depletion and genetic variations in the genes involved in BH4 metabolism have been associated with hypertension, suggesting that BH4 may play a role in the pathogenesis of hypertension. The maternity center of Tunis ( CMNT ) is a level 3 maternity center, supporting over 12 000 births yearly, where the caesarean section's rate is very high, close to 45% of deliveries. Early detection of these patients can help control maternal and neonatal safety outcomes. we can avoid complications such as severe preeclampsia, HELLP syndrom and eclampsia for the mother, and preterm delievery and fetal growth restriction for the new born. in the literature, studies have reported a decrease in BH4 levels in pregnant women compared to non-pregnant women and others showed that its deficiency or depletion has been associated with hypertension. Moreover, tetrahydrobiopterin administration has been studied as a potential treatment for preeclampsia but the optimal dose has not yet been determined, and further studies are needed to determine the appropriate dose, timing, and duration of BH4 supplementation in this context. Thus, BH4 blood levels as a mean of screening, could enrich our diagnostic arsenal. The purpose of our study is to compare BH4 levels between preeclamptic and normotensive women.


Description:

The investigators will conduct a monocentric , prospective, observational study, including 300 pregnant women (150 normotensive and 150 preeclamptic). The participants will be divided into 2 equal groups : - Group P : Preclampsia - Group N : Normotensive After written and informed consent are obtained, a standard battery of blood tests including serum BH4 will be runned for the eligible patients at any moment from the admission to the end of the pregnancy. Baseline data will be collected at enrollment, including demographic and medical history information, blood pressure, proteinuria, and blood samples for BH4 and other biomarker measurements. Follow-up data will be collected at delivery, including blood pressure, proteinuria, and fetal growth measurements, as well as maternal and neonatal outcomes; After collecting all groups, blood samples will be analysed for BH4.


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date December 6, 2023
Est. primary completion date July 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Women aged over 18 YEARS - informed consent - Pregnant - Term of pregnancy over than 24 weeks of gestation - Having a normal pregnancy ( for the control group) - Being diagnosed with preeclampsia or severe preeclampsia as defined in international guidelines (for the case group) Non- inclusion Criteria: - Women with known phenylketonuria - Any history of ( treated or not) hypertension prior to the current pregnancy - Any history of ( treated or not) diabetes or gestational diabetes during the current pregnancy - Any history of renal failure or kidney injury) in the current pregnancy - Women under long-term medications for arterial hypertension or before 24 week of the current pregnancy

Study Design


Intervention

Diagnostic Test:
BH4 blood level
from admission to END OF PREGNANCY, a blood sample is taken.

Locations

Country Name City State
Tunisia Tunis maternity and neonatology center, minisetry of public health Tunis

Sponsors (1)

Lead Sponsor Collaborator
University Tunis El Manar

Country where clinical trial is conducted

Tunisia, 

Outcome

Type Measure Description Time frame Safety issue
Other the association between BH4 blood level (ng/mL) and preterm delivery (before 37 weeks of pregnancy) Secondary outcome measures will include the predectivity of preterm delivery with BH4 levels From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks)
Other the association between BH4 blood level (ng/mL) and fetal growth restriction. Secondary outcome measures will include the association between BH4 levels and fetal growth restriction. From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks)
Other the association between BH4 blood level (ng/mL) and placenta abroptio econdary outcome measures will include the association between BH4 levels and placenta abroptio From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks)
Other the association between BH4 blood level (ng/mL) and mortality predectivity of maternal and foetal mortality by BH4 levels From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks)
Primary the association between BH4 blood level (ng/mL) and severity of preeclampsia (biological and clinical criteria) The primary outcome measure will be the association between BH4 levels and the severity of preeclampsia, including maternal and fetal complications Preeclampsia is defined by : Systolic blood pressure (SBP) higher than 140 mmHg or/and diastolic blood pressure (DBP)higher than 90 mmHg whith proteinuria higher than 0.3 g/24 h
Its sevrity is defined by at least one of those criteria:
SBP > 160 mmHg and/or DBP >110 mmHg
proteinuria > 3g/24h
creatini level > 90 µmol/ l
oliguria < 500 ml /24 hours or < 25 ml/ h
thrombocytopenia < 100.000/mm3
Cytolysis > two times the normal value
neurosensory signs
chest pain , acute lung edema, dyspnea
From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks)
Secondary the association between BH4 blood level (ng/mL) and gestational hypertension. Secondary outcome measures will include the associationtion between BH4 levels and gestational hypertension.
gestational hypertension are defined by High Blood pressure SBP > 160 mmHg and/or DBP > 90 mmHg without proteinuria or any other preeclamptic criteria
From date of first admission until the date of foetal extraction, starting from 20 weeks of pregnancy to it's end (Maximal time frame : 22 weeks)
See also
  Status Clinical Trial Phase
Completed NCT01946113 - Mineral-Homeostasis in Continuous Renal Replacement Therapy N/A
Withdrawn NCT00993733 - Assessing the Impact of Two Methods of Continuous Veno-venous Hemodiafiltration on Time Nursing Work in Intensive Care N/A
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Terminated NCT00978354 - Furosemide in Early Acute Kidney Injury Phase 2/Phase 3
Completed NCT00120263 - Trial of Plasma Exchange for Acute Renal Failure at the Onset of Myeloma N/A
Completed NCT04799600 - The Effect of the Severity of COVID-19 Disease on the Incidence of Acute Renal Failure in ICU
Recruiting NCT04334707 - Kidney Precision Medicine Project
Completed NCT02858531 - Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics
Recruiting NCT05282732 - Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients
Completed NCT01467466 - Prevention of Serious Adverse Events Following Angiography Phase 3
Completed NCT01979042 - Urinary Markers for Unilateral Kidney Obstruction N/A
Completed NCT01280617 - Low Dose Thymoglobin in Renal Transplant Patients N/A
Completed NCT00780351 - Dosing Vancomycin in Patients on Sustained Low Efficiency Daily Hemodiafiltration (SLEDD-f) N/A
Completed NCT00971971 - Prevention of Intradialytic Hypotension in Acute Kidney Injury Patients N/A
Completed NCT00076219 - Acute Renal Failure Trial Network (ATN) Study Phase 3
Recruiting NCT04599569 - Influence of Renal Replacement TherApy on Indirect Calorimetry
Completed NCT03727204 - Acute Kidney Injury After Cardiac Surgery: Novel Ultrasound Techniques for Prediction of Acute Kidney Injury
Completed NCT06005896 - A Clinical Model for Dialysis Discontinuation in AKI
Completed NCT03627884 - Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation Phase 4
Completed NCT03004950 - Biomarker Effectiveness Analysis in Contrast Nephropathy (BEACON)